American Heart Journal
Volume 154, Issue 1 , Pages 94-101 , July 2007

Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)

  • Michael Böhm, MD

      Affiliations

    • Klinik für Innere Medizin III des Universitätsklinikum des Saarlandes, Saarland, Homburg, Germany
    • Corresponding Author InformationReprint requests: Michael Böhm, MD, Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, 66421 Homburg/Saar, Germany.
    • Both authors contributed equally.
    • ,
  • Magnus Baumhäkel, MD

      Affiliations

    • Klinik für Innere Medizin III des Universitätsklinikum des Saarlandes, Saarland, Homburg, Germany
    • Both authors contributed equally.
    • ,
  • Jeffrey L. Probstfield, MD

      Affiliations

    • Department of Cardiology, University of Washington, Seattle, WA
    • ,
  • Roland Schmieder, MD

      Affiliations

    • Medizinische Klinik 4, Universität Erlangen-Nürnberg, Erlangen, Germany
    • ,
  • Salim Yusuf, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Feng Zhao, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Teo Koon, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • On Behalf of the ONTARGET/TRANSCEND ED-Investigators

Received 18 December 2006 ,Accepted 15 March 2007.

References 

  1. National Institutes of Health consensus statement. Impotence. 1992;10:1
  2. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J. 2006;27:2640–2648
  3. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978–2984
  4. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep. 2002;4:397–401
  5. Cheitlin MD. Erectile dysfunction: the earliest sign of generalized vascular disease?. J Am Coll Cardiol. 2004;43:185–186
  6. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89:251–253
  7. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12:305–311
  8. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61
  9. Juenemann KP, Lue TF, Luo JA, et al. The effect of cigarette smoking on penile erection. J Urol. 1987;138:438–441
  10. McVary KT, Carrier S, Wessells H. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624–1632
  11. Klein R, Klein BE, Lee KE, et al. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care. 1996;19:135–141
  12. Montorsi P, Ravagnani P, Galli S, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27:2632–2639
  13. Grimm RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 Pt 1):8–14
  14. Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol. 1991;146:238–240
  15. Saenz de Tejada I, Goldstein I, Azadzoi K, et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med. 1989;320:1025–1030
  16. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43:179–184
  17. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–2157
  18. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148
  19. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II–mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923
  20. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22:1208–1212
  21. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:27–31
  22. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003;2:29–34
  23. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  24. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  25. Friedrich EB, Teo KK, Bohm M. ACE inhibition in secondary prevention: are the results controversial?. Clin Res Cardiol. 2006;95:61–67
  26. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61
  27. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–326
  28. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139:161–168
  29. Modebe O. Erectile failure among medical clinic patients. Afr J Med Med Sci. 1990;19:259–264
  30. Wei M, Macera CA, Davis DR, et al. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994;140:930–937
  31. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004;43:1405–1411
  32. Barksdale JD, Gardner SF. The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy. 1999;19:573–581
  33. Rosenkranz S, Erdmann E. Interaction between sildenafil and antihypertensive drugs: what is evidence-based?. Dtsch Med Wochenschr. 2001;126:1144–1149
  34. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24:1928–1932
  35. Kifor I, Williams GH, Vickers MA, et al. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol. 1997;157:1920–1925
  36. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11:1244–1247
  37. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321:336–341

PII: S0002-8703(07)00246-3

doi: 10.1016/j.ahj.2007.03.024

American Heart Journal
Volume 154, Issue 1 , Pages 94-101 , July 2007

Article Tools

* Image Usage & Resolution